[Form 4] BIOLIFE SOLUTIONS INC Insider Trading Activity

Rhea-AI Filing Summary

BioLife Solutions (BLFS) disclosed insider stock sales by its President and CEO, who is also a Director. The filing reports three open‑market sales of Common Stock: 35,417 shares at a weighted average price of $26.15 on 11/11/2025; 33,418 shares at $25.88 on 11/12/2025; and 31,165 shares at $25.33 on 11/13/2025.

Following these transactions, the executive’s directly held shares moved from 454,581 to 421,163 and then to 389,998. Each price is a weighted average, with individual trades executed within disclosed ranges.

Insights

Equity Governance Analyst

CEO sold 100,000 shares over three days; holdings now 389,998. Signal is modestly negative, no operational impact or dilution.

The President and CEO of BioLife Solutions (BLFS) reported open‑market sales totaling 100,000 common shares across 11/11/2025, 11/12/2025, and 11/13/2025. Weighted average prices were $26.15, $25.88, and $25.33, respectively. Following these transactions, direct beneficial ownership stands at 389,998 shares. No derivative transactions were reported.

This is a reduction in insider ownership, not an issuance, so there is no dilution. The filing notes sales executed in multiple trades within stated price ranges. It does not disclose a trading plan designation in the excerpt. The activity reflects a change in insider exposure rather than a change in company fundamentals.

Items to watch: subsequent Section 16 filings for continued selling or any offsetting acquisitions, and future disclosures that might clarify trading arrangements. Near term, track whether additional Form 4s change the CEO’s stake from the post‑sale level of 389,998 shares after 11/13/2025.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

DE GREEF RODERICK

(Last) (First) (Middle)

3303 MONTE VILLA PARKWAY

SUITE 310

(Street)

BOTHELL WA 98021

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIOLIFE SOLUTIONS INC [ BLFS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
11/11/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/11/2025		S		35,417	D	$26.15(1)	454,581	D
Common Stock	11/12/2025		S		33,418	D	$25.88(2)	421,163	D
Common Stock	11/13/2025		S		31,165	D	$25.33(3)	389,998	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.85 to $26.63, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.64 to $26.40, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.05 to $25.87, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Remarks:

	/s/ Roderick de Greef	11/13/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did BLFS report?

The President and CEO, also a Director, reported three open‑market sales of BLFS Common Stock on 11/11/2025, 11/12/2025, and 11/13/2025.

How many BLFS shares were sold on 11/11/2025?

35,417 shares at a weighted average price of $26.15.

How many BLFS shares were sold on 11/12/2025?

33,418 shares at a weighted average price of $25.88.

How many BLFS shares were sold on 11/13/2025?

31,165 shares at a weighted average price of $25.33.

What is the executive’s direct BLFS share ownership after the reported trades?

389,998 shares directly owned after the 11/13/2025 transaction.

Were the reported prices single trades or averages?

They are weighted average prices, with multiple trades executed within disclosed price ranges for each day.

Did the filing indicate a Rule 10b5-1 trading plan?

The form includes a 10b5-1 checkbox reference, but no selection status is provided in the excerpt.